Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin

Vaccine

Volumn 27, Issue 13, 2009, Pages 1949-1956

  Rubio, Ivonne ^a   Bolchi, Angelo ^b   Moretto, Nadia ^b   Canali, Elena ^b   Gissmann, Lutz ^a   Tommasino, Massimo ^a   Müller, Martin ^a   Ottonello, Simone ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Human papilloma virus; Minor capsid protein L2; Thioredoxin

Indexed keywords

ANTISERUM; CAPSID PROTEIN; CAPSID PROTEIN L2; THIOREDOXIN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOVIRION; SEQUENCE ANALYSIS; TANDEM REPEAT; UTERINE CERVIX CANCER; VIRION; VIRUS INFECTION; VIRUS NEUTRALIZATION; WART VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CELL LINE; FEMALE; HUMAN PAPILLOMAVIRUS 16; IMMUNE SERA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; TANDEM REPEAT SEQUENCES; THIOREDOXINS;

EID: 61349175777     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.102     Document Type: Article

References (30)

1. Roden R., and Wu T.C. How will HPV vaccines affect cervical cancer?. Nat Rev Cancer 6 (2006) 753-763
2. Schmiedeskamp M.R., and Kockler D.R. Human papillomavirus vaccines. Ann Pharmacother 40 (2006) 1344-1352
3. Villa L.L. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis 11 Suppl. 2 (2007) S17-S25
4. Muller M., and Gissmann L. A long way: history of the prophylactic papillomavirus vaccine. Dis Markers 23 (2007) 331-336
5. Huh W.K., and Roden R.B. The future of vaccines for cervical cancer. Gynecol Oncol 109 (2008) S48-56
6. Giroglou T., Sapp M., Lane C., Fligge C., Christensen N.D., Streeck R.E., et al. Immunological analyses of human papillomavirus capsids. Vaccine 19 (2001) 1783-1793
7. Campo M.S., O'Neil B.W., Grindlay G.J., Curtis F., Knowles G., and Chandrachud L. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology 234 (1997) 261-266
8. Gambhira R., Jagu S., Karanam B., Gravitt P.E., Culp T.D., Christensen N.D., et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81 (2007) 11585-11592
9. Kondo K., Ishii Y., Ochi H., Matsumoto T., Yoshikawa H., and Kanda T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358 (2007) 266-272
10. Gambhira R., Karanam B., Jagu S., Roberts J.N., Buck C.B., Bossis I., et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81 (2007) 13927-13931
11. Yang R., Day P.M., Yutzy W.H., Lin K.Y., Hung C.F., and Roden R.B. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol 77 (2003) 3531-3541
12. Day P.M., Gambhira R., Roden R.B., Lowy D.R., and Schiller J.T. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and l1 type-specific antibodies. J Virol 82 (2008) 4638-4646
13. Kawana Y., Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., and Kanda T. Human papillomavirus type 16 minor capsid protein L2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol 75 (2001) 2331-2336
14. Kawana K., Kawana Y., Yoshikawa H., Taketani Y., Yoshiike K., and Kanda T. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine 19 (2001) 1496-1502
15. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 (2005) 365-372
16. Embers M.E., Budgeon L.R., Pickel M., and Christensen N.D. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 76 (2002) 9798-9805
17. Alphs H.H., Gambhira R., Karanam B., Roberts J.N., Jagu S., Schiller J.T., et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 105 (2008) 5850-5855
18. Moretto N., Bolchi A., Rivetti C., Imbimbo B.P., Villetti G., Pietrini V., et al. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 282 (2007) 11436-11445
19. Blum H., Rollinghoff M., and Gessner A. Expression and co-cytokine function of murine thioredoxin/adult T cell leukaemia-derived factor (ADF). Cytokine 8 (1996) 6-13
20. Bertini R., Howard O.M., Dong H.F., Oppenheim J.J., Bizzarri C., Sergi R., et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 189 (1999) 1783-1789
21. Vincentelli R., Canaan S., Campanacci V., Valencia C., Maurin D., Frassinetti F., et al. High-throughput automated refolding screening of inclusion bodies. Protein Sci 13 (2004) 2782-2792
22. Liu S., Tobias R., McClure S., Styba G., Shi Q., and Jackowski G. Removal of endotoxin from recombinant protein preparations. Clin Biochem 30 (1997) 455-463
23. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., et al. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291 (2001) 324-334
24. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223 (1996) 174-184
25. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76 (2002) 6480-6486
26. Rizk R.Z., Christensen N.D., Michael K.M., Muller M., Sehr P., Waterboer T., et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 89 (2008) 117-129
27. Rice J., Elliott T., Buchan S., and Stevenson F.K. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol 167 (2001) 1558-1565
28. Kawana K., Yasugi T., Kanda T., Kino N., Oda K., Okada S., et al. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21 (2003) 4256-4260
29. Fraillery D., Baud D., Pang S.Y., Schiller J., Bobst M., Zosso N., et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 14 (2007) 1285-1295
30. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22 (1994) 4673-4680